Semaglutide is a human GLP-1 analogue with 94% homology to human GLP-1 with half-life of one week. This novel Semaglutide is suitable for once weekly dosing at a steady state.
This module will explore the Sustain clinical program. Again will look at the CV outcomes of OW Semaglutide
In this module we will explore the latest recommendations for management of type 2 diabetes in most recent international guidelines, the evolution of ADA/EASD consensus, standards of medical care in diabetes, consensus of AADE /ACE 2020, ESC guidelines in Diabetes and CVD and ACC/AHA primary prevention of CVD.
The evolving concept of managing type 2 diabetes for HbA1c to CV Risk reduction with agents of proven safety and efficacy
With the current availability of different antidiabetic classes for management of type 2 diabetes, always the question remains, when & how to place them in the algorithm of treatment. Among these classes are the GLP1 RAs which gained favourable effects.
Here we are going to discuss where to position them in the management algorithm. And then to look inside the GLP1 RA class trying to see whether they are the same or there is a difference among molecules in the class.
Ramadan is very special occasion for all Muslims to observe fasting. It is spiritual event, even for people with diabetes willing to fast despite risks.
Fasting Ramadan for people with diabetes carry high risk for hypoglycaemia as well as hyperglycaemia.
Educating people with diabetes about their risk and selecting safe molecules are essentials in having safe fasting Ramdan
Diabetes Can influence the pathophysiology, susceptibility and the clinical outcome during infection.
Managing blood glucose during infection is very challenging and needs aggressive measures. In patient management of infections and sepsis are different from managing those as out patients. glycaemic targets for critically ill hospitalized patients are different from those managed in the regular daily practice…
People with type 2 diabetes has got multiple cardiovascular risks, addressing these risks in order to reduce the mortality are very important objective in managing them.
GLP1 RA has got multiple action to control glycaemia and other CV risks. GLP1 has shown variable results in terms of cardiovascular benefits in the cardiovascular trials CVOTs.
As a result this has got its implications on the latest diabetes treatment guidelines
COVID-19 is very contagious, infectious to all people at risk and contact people with diabetes and other comorbid conditions like CVD are at high risk of sever disease & high mortality.
Management of individuals with diabetes during the COVID-19 critical period is very important.
This Module will cover the COVID-19 overview, the recommendations of treating it as well as management of diabetes during COVID-19 infection